SP

Scott McAuley, PhD

Head Of Research at Paradigm Capital

Scott McAuley, PhD, has diverse work experience spanning different roles and industries.

Scott currently serves as the Head of Research at Paradigm Capital, where they oversee research initiatives. Prior to this, they worked as an Equity Research Analyst in the healthcare and biotechnology sector at the same company.

From 2010 to 2019, Scott was the Communications Coordinator at the Impact Centre at the University of Toronto. In this role, they were responsible for managing and coordinating communication efforts.

Scott also has a strong background in academia. Scott conducted extensive research as a PhD Researcher at the University of Toronto from 2013 to 2019. Their research program in the Department of Biochemistry led to the discovery and description of the mechanism of action of novel antibiotic small molecules. Scott effectively disseminated their findings through published manuscripts, conference posters, and presentations.

Additionally, Scott co-founded and served as a Director at Lunanos from 2010 to 2014.

During their time at the University of Toronto from 2008 to 2010, Scott worked as a Teaching Assistant, where they taught tutorials, supervised laboratory sessions, and marked assessments for various courses. Scott also conducted research as a Master's Researcher during this period.

Overall, Scott McAuley, PhD, possesses a strong academic background, research experience, and industry expertise, enabling him to excel in leadership and analytical roles.

Dr. Scott McAuley earned their Bachelor of Science (BSc) degree in Chemistry from McGill University, where they studied from 2004 to 2008. Scott then pursued a Master of Science (MSc) degree in Chemistry at the University of Toronto from 2008 to 2010. Continuing their academic career, they obtained their highest degree, a Doctor of Philosophy (PhD) in Biochemistry, also from the University of Toronto, where they studied from 2013 to 2019.

Links

Timeline

  • Head Of Research

    June, 2022 - present

  • Equity Research Analyst, Healthcare and Biotechnology

    July, 2019

View in org chart